丁酸氢化可的松结构式
|
常用名 | 丁酸氢化可的松 | 英文名 | Hydrocortisone 17-butyrate |
|---|---|---|---|---|
| CAS号 | 13609-67-1 | 分子量 | 432.550 | |
| 密度 | 1.2±0.1 g/cm3 | 沸点 | 585.6±50.0 °C at 760 mmHg | |
| 分子式 | C25H36O6 | 熔点 | 212 °C | |
| MSDS | 中文版 美版 | 闪点 | 194.0±23.6 °C |
丁酸氢化可的松用途【用途一】 激素。 |
| 中文名 | 丁酸氢化可的松 |
|---|---|
| 英文名 | cortisol 17-butyrate |
| 中文别名 | 氢化可的松17-丁酸酯 | 17-丁酸皮质醇酯 | 氢化可的松17丁酸杂质 | 17-丁酸11β,17,21-三羟基孕-4-烯-3,20-二酮 | 氢化可的松丁酸酯 | 氢化可的松丁酸酯 |
| 英文别名 | 更多 |
| 描述 | Hydrocortisone 17-butyrate是肾上腺皮质激素类药物。 |
|---|---|
| 相关类别 |
| 密度 | 1.2±0.1 g/cm3 |
|---|---|
| 沸点 | 585.6±50.0 °C at 760 mmHg |
| 熔点 | 212 °C |
| 分子式 | C25H36O6 |
| 分子量 | 432.550 |
| 闪点 | 194.0±23.6 °C |
| 精确质量 | 432.251190 |
| PSA | 100.90000 |
| LogP | 2.81 |
| 外观性状 | 固体;White to Almost white powder to crystal |
| 蒸汽压 | 0.0±3.7 mmHg at 25°C |
| 折射率 | 1.565 |
| 储存条件 | 室温 |
| 计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:2 3.氢键受体数量:6 4.可旋转化学键数量:6 5.互变异构体数量:15 6.拓扑分子极性表面积:101 7.重原子数量:31 8.表面电荷:0 9.复杂度:817 10.同位素原子数量:0 11.确定原子立构中心数量:7 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
| 个人防护装备 | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| 危害码 (欧洲) | Xn |
| 危险品运输编码 | NONH for all modes of transport |
| WGK德国 | 2 |
| RTECS号 | GM9002000 |
| 海关编码 | 2937210000 |
|
~79%
丁酸氢化可的松 13609-67-1 |
| 文献:Sugai; Okazaki; Akaboshi Synthesis, 1984 , vol. NO. 8, p. 700 - 701 |
|
~%
丁酸氢化可的松 13609-67-1 |
| 文献:US4290962 A1, ; |
|
~%
丁酸氢化可的松 13609-67-1 |
| 文献:Steroids, , vol. 42, # 1 p. 23 - 36 |
| 丁酸氢化可的松上游产品 2 | |
|---|---|
| 丁酸氢化可的松下游产品 1 | |
| 海关编码 | 2937210000 |
|---|
|
Convenient QSAR model for predicting the complexation of structurally diverse compounds with β-cyclodextrins
Bioorg. Med. Chem. 17 , 896-904, (2009) This paper reports a QSAR study for predicting the complexation of a large and heterogeneous variety of substances (233 organic compounds) with beta-cyclodextrins (beta-CDs). Several different theoret... |
|
|
Synergistic topical application of salt-processed Phellodendron amurense and Sanguisorba officinalis Linne alleviates atopic dermatitis symptoms by reducing levels of immunoglobulin E and pro-inflammatory cytokines in NC/Nga mice.
Mol. Med. Report. 12 , 7657-64, (2015) Atopic dermatitis is a chronic inflammatory skin disease, and salt-processed Phellodendron amurense (CPE) and Sanguisorba officinalis Linne (SOE) are widely used as anti-inflammatory agents in Asia. T... |
|
|
Statistical design for formulation optimization of hydrocortisone butyrate-loaded PLGA nanoparticles.
AAPS PharmSciTech 15(3) , 569-87, (2014) The aim of this investigation was to develop hydrocortisone butyrate (HB)-loaded poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles (NP) with ideal encapsulation efficiency (EE), particle size, an... |
| LOCOID LIPOCREAM |
| 11b,17,21-Trihydroxypregn-4-ene-3,20-dione 17-Butyrate |
| Pregn-4-ene-3,20-dione, 11,21-dihydroxy-17-(1-oxobutoxy)-, (11β)- |
| butanoate de (8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-17-(hydroxyacétyl)-10,13-diméthyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tétradécahydro-1H-cyclopenta[a]phénanthrén-17-yle |
| Hydrocortisone Butyrate |
| Hydrocortisone butyrate (JP15/USP) |
| (8S,9S,10R,11S,13S,14S,17R)-11-Hydroxy-17-(hydroxyacetyl)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ylbutanoat |
| Hydrocortisone 17-butyrate |
| (11β)-11,21-Dihydroxy-17-(1-oxobutoxy)pregn-4-ene-3,20-dione |
| cortisol 17-butyrate |
| MFCD00083364 |
| EINECS 237-093-4 |
| 11β,17,21-Trihydroxypregn-4-ene-3,20-dione 17-Butyrate |
| (11β)-11,21-Dihydroxy-3,20-dioxopregn-4-en-17-yl butyrate |
| Butanoic acid, (11β)-11,21-dihydroxy-3,20-dioxopregn-4-en-17-yl ester |
| (8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-17-(hydroxyacetyl)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl butanoate |
| locoid |
| (11β)-11,21-dihydroxy-3,20-dioxopregn-4-en-17-yl butanoate |
| Hydrocortisone butyrate [USAN:BAN:JAN] |
| Pregn-4-ene-3,20-dione, 11,21-dihydroxy-17-(1-oxobutoxy)-, (11-β)- |
| [(8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] butanoate |